Heart Failure News and Research RSS Feed - Heart Failure News and Research

Heart failure (HF) is a condition in which a problem with the structure or function of the heart impairs its ability to supply sufficient blood flow to meet the body's needs. It should not be confused with cardiac arrest or myocardial infarction.
Finerenone effective in heart failure patients with diabetes and/or chronic kidney disease

Finerenone effective in heart failure patients with diabetes and/or chronic kidney disease

In heart failure patients with diabetes and/or chronic kidney disease, a new, non-steroidal mineralocorticoid receptor antagonist (MRA) called finerenone was no more effective than the currently approved MRA eplerenone in reducing the heart failure biomarker N-terminal pro-B-type natriuretic peptide [NT-proBNP]. [More]
Defibrillator does not improve outcomes in patients with CRT pacemaker

Defibrillator does not improve outcomes in patients with CRT pacemaker

Most patients with a cardiac resynchronisation therapy (CRT) pacemaker would not benefit from the addition of a defibrillator, according to results from the CeRtiTuDe cohort study presented for the first time today at ESC Congress1 and published in European Heart Journal. [More]
GARFIELD-AF Registry: All-cause death is most frequent major event in newly diagnosed AF patients

GARFIELD-AF Registry: All-cause death is most frequent major event in newly diagnosed AF patients

The first-ever two-year outcomes from the Global Anticoagulant Registry in the Field - Atrial Fibrillation (GARFIELD-AF) showcased at ESC Congress 2015 expose that all-cause death was the most frequent major event in more than 17,000 newly diagnosed AF patients, far exceeding the rate of stroke or major bleeding. [More]
Janssen, Bayer HealthCare announce results from landmark studies evaluating safety profile of XARELTO in NVAF patients

Janssen, Bayer HealthCare announce results from landmark studies evaluating safety profile of XARELTO in NVAF patients

Janssen Pharmaceuticals, Inc., and its development partner, Bayer HealthCare, today announced results from PMSS (Post-Marketing Safety Surveillance) and XANTUS (XARELTO for Prevention of Stroke in Patients with Atrial Fibrillation), their landmark real-world studies evaluating the safety of XARELTO in people with non-valvular atrial fibrillation (NVAF). [More]
Two new pilot programs launched to reduce hospital readmissions, ease overcrowding in ERs and lower healthcare costs

Two new pilot programs launched to reduce hospital readmissions, ease overcrowding in ERs and lower healthcare costs

The UCLA Center for Prehospital Care and collaborators from the Los Angeles County Emergency Medical Services (EMS) agency and the Glendale and Santa Monica fire departments are launching two pilot programs designed to reduce hospital readmissions, address overcrowding in emergency rooms, lower healthcare costs and boost patient satisfaction and quality of life. [More]
Pie Medical Imaging receives 2015 European Frost & Sullivan Award for Technology Leadership

Pie Medical Imaging receives 2015 European Frost & Sullivan Award for Technology Leadership

Based on its recent analysis of the cardiovascular image management market, Frost & Sullivan recognizes Pie Medical Imaging (PMI) with the 2015 European Frost & Sullivan Award for Technology Leadership. [More]
ICDs with automated pulmonary congestion alert do not improve outcomes in heart failure patients

ICDs with automated pulmonary congestion alert do not improve outcomes in heart failure patients

Heart failure patients whose implantable cardioverter defibrillators (ICDs) include an automated alert when too much fluid accumulates in their lungs did not have improved outcomes compared to patients with regular ICDs, according to results of the OPTILINK HF trial. [More]
Gene transfer therapy not beneficial for heart failure patients with reduced ejection fraction

Gene transfer therapy not beneficial for heart failure patients with reduced ejection fraction

Gene transfer therapy aimed at correcting an enzyme abnormality involved in myocardial contraction and relaxation did not improve outcomes in heart failure patients with reduced ejection fraction, results of the CUPID 2 study show. [More]
BCM injection does not prevent cardiac remodeling in heart attack patients

BCM injection does not prevent cardiac remodeling in heart attack patients

An investigational material known Bioabsorbable Cardiac Matrix (BCM) that is injected through the coronary artery to prevent cardiac remodelling in heart attack patients had no significant effect compared to a saline placebo, according to results of the PRESERVATION I trial. [More]
Benznidazole has significant antiparasitic activity, but does not reduce progression of Chagas cardiomyopathy

Benznidazole has significant antiparasitic activity, but does not reduce progression of Chagas cardiomyopathy

A 40 to 80 day treatment with the antiparasitic medication benznidazole significantly reduced parasite activity in the blood, but not progression, of serious heart problems over a 5-year period among patients with established Chagas disease (CD) cardiomyopathy, results of the BENEFIT trial show. [More]
ASV therapy used to treat central sleep apnoea in heart failure patients increases mortality

ASV therapy used to treat central sleep apnoea in heart failure patients increases mortality

Adaptive servo-ventilation (ASV) therapy increases mortality and should not be used to treat central sleep apnoea in heart failure patients with reduced ejection fraction, the SERVE-HF trial shows. [More]
Study: Inner-city neighbourhoods may affect risk of dying from cardiovascular disease

Study: Inner-city neighbourhoods may affect risk of dying from cardiovascular disease

The inner-city neighbourhood in which someone lives may affect his or her risk of developing or dying from cardiovascular disease, a new research paper suggests. [More]
After acute myocardial infarction, respiratory infection associated with increased risk of mortality

After acute myocardial infarction, respiratory infection associated with increased risk of mortality

Respiratory infection is associated with a four-fold increased risk of in-hospital cardiovascular mortality after acute myocardial infarction (AMI), according to research presented at ESC Congress today by Dr Catarina Quina-Rodrigues, a cardiologist at Hospital de Braga in Portugal. The findings highlight the importance of diagnostic alertness for respiratory infections in AMI patients so that therapeutic measures can be promptly taken. [More]
LCZ696 reduces aortic systolic blood pressure, pulse pressure in hypertensive patients

LCZ696 reduces aortic systolic blood pressure, pulse pressure in hypertensive patients

The combination drug valsartan/sacubitril known as LCZ696 significantly reduced aortic systolic blood pressure and pulse pressure compared to the standard angiotensin receptor blocker (ARB) olmesartan in patients with hypertension, according to results of the PARAMETER study. [More]
TECOS analysis shows sitagliptin safe and effective in patients with type-2 diabetes, cardiovascular disease

TECOS analysis shows sitagliptin safe and effective in patients with type-2 diabetes, cardiovascular disease

Patients with type-2 diabetes and cardiovascular disease can safely take the antihyperglycemic drug sitagliptin without an increased risk of cardiovascular complications - even if they have a history of heart failure - a new analysis of the TECOS (Trial Evaluating Cardiovascular Outcomes with Sitagliptin) study shows. [More]
Depression, blood pressure predict harmful vascular events in patients with heart disease, diabetes or stroke

Depression, blood pressure predict harmful vascular events in patients with heart disease, diabetes or stroke

Depressive symptoms and extremes of blood pressure predict the highest rates of harmful vascular events in patients with existing heart disease, diabetes or stroke, according to research presented at ESC Congress today by Dr Bhautesh Jani, clinical academic fellow in the Institute of Health and Wellbeing, University of Glasgow, UK. [More]
ELIXA trial results demonstrate cardiovascular safety of lixisenatide drug

ELIXA trial results demonstrate cardiovascular safety of lixisenatide drug

In patients with type 2 diabetes and acute coronary syndrome, the glucose-lowering medication lixisenatide did not increase or decrease the rate of cardiovascular (CV) events compared to placebo, according to results of the Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) trial. [More]
Stroke prevention strategies in elderly should focus on multiple risk factors

Stroke prevention strategies in elderly should focus on multiple risk factors

The impact of atrial fibrillation on ischaemic stroke risk in elderly patients is eliminated with multiple risk factors, according to an 11 year study in more than 425 000 patients presented at ESC Congress today. [More]
MRA therapy does not improve outcome in heart attack patients without heart failure

MRA therapy does not improve outcome in heart attack patients without heart failure

Heart attack patients without heart failure derive no benefit from the addition of mineralocortoid receptor antagonists (MRA), to standard therapy, results of the ALBATROSS study show. [More]

Cyclosporine drug does not improve outcomes in STEMI patients receiving PCI

The immunosuppressant drug cyclosporine did not improve clinical outcomes compared to placebo in patients receiving percutaneous coronary intervention (PCI) for the more severe form of heart attack known as ST-segment elevation myocardial infarction (STEMI). [More]
Advertisement